Welcome to LookChem.com Sign In|Join Free

CAS

  • or

215868-23-8

Post Buying Request

215868-23-8 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

215868-23-8 Usage

Description

6,8-Difluoro-7-hydroxy-4-methylcoumarin (DIFMU) is a synthetic compound belonging to the class of coumarins, which are organic compounds that possess a variety of biological and chemical properties. DIFMU is characterized by its fluorine substitution at the 6 and 8 positions, a hydroxyl group at the 7 position, and a methyl group at the 4 position. These structural features contribute to its unique properties and potential applications in various fields.

Uses

Used in Diagnostic Applications:
6,8-DIFLUORO-7-HYDROXY-4-METHYLCOUMARIN is used as a diagnostic agent for the detection of natural killer (NK) cell activity. The expression is: 6,8-DIFLUORO-7-HYDROXY-4-METHYLCOUMARIN is used as a diagnostic agent for [application reason] the detection of natural killer cell-activity.
In the field of immunology, DIFMU serves as a valuable tool for assessing the functionality of NK cells, which are crucial components of the immune system. NK cells play a vital role in the defense against viral infections and cancer by recognizing and eliminating infected or transformed cells. The use of DIFMU in diagnostic assays allows researchers and clinicians to evaluate the effectiveness of NK cell-mediated immune responses, which can be crucial in understanding and managing various diseases.
Used in Pharmaceutical Research:
6,8-DIFLUORO-7-HYDROXY-4-METHYLCOUMARIN is used as a research compound in the development of new drugs and therapies. The expression is: 6,8-DIFLUORO-7-HYDROXY-4-METHYLCOUMARIN is used as a research compound for [application reason] the development of new drugs and therapies.
In the pharmaceutical industry, DIFMU can be employed as a starting material or a structural motif for the synthesis of novel drug candidates. Its unique chemical properties, such as the presence of fluorine atoms and the hydroxyl group, can be exploited to design molecules with improved pharmacokinetic and pharmacodynamic profiles. Additionally, the coumarin core of DIFMU is a well-known scaffold in medicinal chemistry, with numerous examples of bioactive compounds derived from this structure.
Used in Chemical Synthesis:
6,8-DIFLUORO-7-HYDROXY-4-METHYLCOUMARIN is used as a synthetic intermediate for the preparation of various chemical compounds. The expression is: 6,8-DIFLUORO-7-HYDROXY-4-METHYLCOUMARIN is used as a synthetic intermediate for [application reason] the preparation of various chemical compounds.
DIFMU's structural features make it an attractive building block for the synthesis of a wide range of organic compounds, including pharmaceuticals, agrochemicals, and specialty chemicals. Its reactivity can be further enhanced through functional group manipulation, allowing for the introduction of additional functional groups or the formation of complex molecular architectures. This versatility makes DIFMU a valuable asset in the field of chemical synthesis.

Check Digit Verification of cas no

The CAS Registry Mumber 215868-23-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,1,5,8,6 and 8 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 215868-23:
(8*2)+(7*1)+(6*5)+(5*8)+(4*6)+(3*8)+(2*2)+(1*3)=148
148 % 10 = 8
So 215868-23-8 is a valid CAS Registry Number.

215868-23-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 16, 2017

Revision Date: Aug 16, 2017

1.Identification

1.1 GHS Product identifier

Product name H-LYS-LYS-LYS-LYS-LYS-OH

1.2 Other means of identification

Product number -
Other names 6,8-DIFLUORO-7-HYDROXY-4-METHYLCOUMARIN

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:215868-23-8 SDS

215868-23-8Relevant articles and documents

Measurements of kinetic parameters in a microfluidic reactor

Kerby, Matthew B.,Legge, Robert S.,Tripathi, Anubhav

, p. 8273 - 8280 (2006)

Continuous flow microfluidic reactors that use immobilized components of enzymatic reactions present special challenges in interpretation of kinetic data. This study evaluates the difference between mass-transfer effects and reduced efficiencies of an enz

Deglycase-activity oriented screening to identify DJ-1 inhibitors

David, Yael,Finkin-Groner, Efrat,Fukase, Yoshiyuki,Huggins, David J.,Maksimovic, Igor,Michino, Mayako,Myers, Robert W.,Sun, Shan,Zheng, Qingfei

supporting information, p. 1232 - 1238 (2021/09/28)

The oncoprotein and Parkinson's disease-associated enzyme DJ-1/PARK7 has emerged as a promiscuous deglycase that can remove methylglyoxal-induced glycation adducts from both proteins and nucleotides. However, dissecting its structural and enzymatic functions remains a challenge due to the lack of potent, specific, and pharmacokinetically stable inhibitors targeting its catalytic site (including Cys106). To evaluate potential drug-like leads against DJ-1, we leveraged its deglycase activity in an enzyme-coupled, fluorescence lactate-detection assay based on the recent understanding of its deglycation mechanism. In addition, we developed assays to directly evaluate DJ-1's esterase activity using both colorimetric and fluorescent substrates. The resulting optimized assay was used to evaluate a library of potential reversible and irreversible DJ-1 inhibitors. The deglycase activity-oriented screening strategy described herein establishes a new platform for the discovery of potential anti-cancer drugs.

PROTEASOME INHIBITOR COMPRISING A SIGNAL-EMITTING MOIETY

-

Page/Page column 31; 32, (2017/03/14)

The present invention relates to compounds such as peptides which act as proteasome inhibitors. The compounds are covalently linked with a signal emitting compound or a precursor thereof, via an ester such as a sulfonic ester group for imaging of the inhibition of the proteasome. The compound is for use in the quantification of proteasomal inhibition, diagnosis and/or prevention and/or treatment of autoimmune diseases, cancer, neurodegenerative diseases, viral infections and/or diseases associated with inflammation. The invention further relates to methods to produce the compounds.

Development of highly potent inhibitors of the ras-targeting human acyl protein thioesterases based on substrate similarity design

Hedberg, Christian,Dekker, Frank J.,Rusch, Marion,Renner, Steffen,Wetzel, Stefan,Vartak, Nachiket,Gerding-Reimers, Claas,Bon, Robin S.,Bastiaens, Philippe I. H.,Waldmann, Herbert

supporting information; experimental part, p. 9832 - 9837 (2011/12/02)

A matter of common sense: A common recognition motif consisting of a negatively charged group five to six bonds away (red) from the (thio)ester functionality (green) and a positively charged tail group ten to twelve bonds away (blue) was identified in two

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 215868-23-8